Molecular tumor profiling for prediction of response to anticancer therapies

Cancer Journal

Volumn 17, Issue 2, 2011, Pages 71-79

  Walther, Zenta ^a   Sklar, Jeffrey ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

mutation analysis; predictive tumor markers; targeted therapies; Tumor profiling

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GROWTH FACTOR RECEPTOR; IMATINIB; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLX 4032; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR;

CHROMOSOME ABERRATION; DISEASE MARKER; DNA SEQUENCE; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC ANALYSIS; GENOMICS; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; ONCOGENE N RAS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR RESISTANCE;

DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENETIC TESTING; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 79954517618     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318212dd6d     Document Type: Review

References (51)

1. Grimwade D, Mistry AR, Solomon E, et al. Acute promyelocytic leukemia: a paradigm for differentiation therapy. Cancer Treat Res. 2010;145: 219-235.
2. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J Clin Oncol. 2002;20: 719-726. (Pubitemid 34111379)
3. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652. (Pubitemid 34815868)
4. Liegl-Atzwanger B, Fletcher JA, Fletcher CD. Gastrointestinal stromal tumors. Virchows Arch. 2010;456:111-127.
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermalgrowth factor receptor underlying responsiveness of non-smallcell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139. (Pubitemid 38637993)
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304:1497-1500. (Pubitemid 38720929)
7. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from ''never smokers'' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306-13311. (Pubitemid 39209661)
8. Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol. 2010;80:568-574.
9. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363: 809-819.
10. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363: 1693-1703.
11. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008; 68:3077-3080.
12. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.
13. Roberts PJ, Stinchcombe TE, Der CJ, et al. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol. 2010;28:4769-4777.
14. Jabbour E, Branford S, Saglio G, et al. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2010. doi:10.1002/cncr/25717.
15. Hochhaus A. Cytogenetic and molecular mechanisms of resistance to imatinib. Semin Hematol. 2003;40:69-79. (Pubitemid 36687163)
16. Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216:64-74.
17. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2008;14:2895-2899.
18. Yano S,WangW, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008;68:9479-9487.
19. Giamas G, Man YL, Hirner H, et al. Kinases as targets in the treatment of solid tumors. Cell Signal. 2010;22:984-1002.
20. Ardini E, Magnaghi P, Orsini P, et al. Anaplastic lymphoma kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy. Cancer Lett. 2010;299:81-94.
21. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALKrearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010; 363:1727-1733.
22. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98:1817-1824. (Pubitemid 350002184)
23. Fan QW, Weiss WA. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr Top Microbiol Immunol. 2010; 347:279-296.
24. Mitra S, Li G, Harsh GR. Passive antibody-mediated immunotherapy for the treatment of malignant gliomas. Neurosurg Clin N Am. 2010; 21:67-76.
25. Li G, Mitra S,Wong AJ. The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas. Neurosurg Clin N Am. 2010;21:87-93.
26. Moelans CB, van Diest PJ, Milne AN, et al. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int. 2010; 2011:674182.
27. Konecny GE, Santos L, Winterhoff B, et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer. 2009;100: 89-95.
28. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005; 65:1642-1646. (Pubitemid 40478587)
29. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med. 2006;354:2619-2621. (Pubitemid 43882374)
30. Fenner MH, Beutel G, Grunwald V. Targeted therapies for patients with germ cell tumors. Expert Opin Investig Drugs. 2008;17:511-522. (Pubitemid 351578169)
31. Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol. 2010;3:497-516.
32. Cheng L, Roth LM, Zhang S, et al. KIT gene mutation and amplification in dysgerminoma of the ovary. Cancer. 2010. doi:10.1002/cncr.25794.
33. Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res. 2009; 15:7510-7518.
34. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7:504-516. (Pubitemid 351767118)
35. Lorenzato A, Olivero M, Patane S, et al. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res. 2002;62:7025-7030. (Pubitemid 35424097)
36. Fumagalli D, Gavin PG, Taniyama Y, et al. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer. 2010;10:101.
37. Eder JP, Vande Woude GF, Boerner SA, et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009;15:2207-2214.
38. Di Nicolantonio F, Arena S, Tabernero J, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010;120:2858-2866.
39. Davies MA, Samuels Y. Analysis of the genome to personalize therapy for melanoma. Oncogene. 2010;29:5545-5555.
40. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973-977.
41. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wildtype KRAS metastatic colon cancer. J Clin Oncol. 2009;27:5924-5930.
42. Kopetz S, Desai J, Chan E, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol. 2010; 28(suppl):15s, Abstract 3534.
43. Lackner MR. Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways. Expert Rev Mol Diagn. 2010;10: 75-87.
44. Cully M, You H, Levine AJ, et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006;6:184-192. (Pubitemid 43292562)
45. Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol. 2010;347:21-41.
46. Kadota M, Sato M, Duncan B, et al. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res. 2009;69:7357-7365.
47. Schleinitz D, Distefano JK, Kovacs P. Targeted SNP genotyping using the TaqMan(R) assay. Methods Mol Biol. 2011;700:77-87.
48. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2:146-158.
49. Li H, Wang J, Ma X, et al. Gene fusions and RNA trans-splicing in normal and neoplastic human cells. Cell Cycle. 2009;8:218-222.
50. Zhou X, Ren L, Meng Q, et al. The next-generation sequencing technology and application. Protein Cell. 2010;1:520-536.
51. Datta S, Datta S, Kim S, et al. Statistical analyses of next generation sequence data: a partial overview. J Proteomics Bioinform. 2010;3: 183-190.